过去一年中添加的文章，按日期排序
[引用][C] HTA72 Molnupiravir for Treatment of Non-Hospitalized Adults With Laboratory-Confirmed, Mild/Moderately Severe COVID-19: A Systematic Evidence Review …
GN Okoli, N Askin, R Rabbani - Value in Health, 2024 - valueinhealthjournal.com
20 天前 - … systematically searched for randomised controlled trials (RCTs) of molnupiravir for
COVID-19 … We conducted pooled analysis of appropriate data using an inverse variance, …
COVID-19 … We conducted pooled analysis of appropriate data using an inverse variance, …
[HTML][HTML] Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review
J Richmond DiBello, VT Raziano, X Liu… - Infectious Diseases and …, 2024 - Springer
38 天前 - … current study was to conduct a systematic literature review … of molnupiravir, including
effectiveness against COVID-19 … We found that treatment with molnupiravir was effective in …
effectiveness against COVID-19 … We found that treatment with molnupiravir was effective in …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
198 天前 - … Our systematic review and network meta-analysis evaluated the efficacy and safety
of … /ritonavir, and molnupiravir) for treating mild to moderate COVID-19 outpatients. We …
of … /ritonavir, and molnupiravir) for treating mild to moderate COVID-19 outpatients. We …
EE340 Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore.
Z Junyang, MIA Aziz, SKB Ong, KH Ng - Value in Health, 2023 - valueinhealthjournal.com
203 天前 - … Objectives: This study evaluates the cost-effectiveness of molnupiravir against
standard care for treating mild to moderate COVID-19 infection at high risk of severe disease in …
standard care for treating mild to moderate COVID-19 infection at high risk of severe disease in …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors' response
M Sun, H Lai, Z Zhang, L Ge - Journal of Antimicrobial …, 2023 - academic.oup.com
238 天前 - … We would like to emphasize that systematic reviews are evidence to support …
Molnupiravir was developed for the outpatient treatment of mild to moderate COVID-19 in adults. Its …
Molnupiravir was developed for the outpatient treatment of mild to moderate COVID-19 in adults. Its …
Population pharmacokinetics of molnupiravir in adults with COVID‐19: lack of clinically important exposure variation across individuals
259 天前 - … was administered at 200, 400, or 800 mg q12h for 5 days to participants for treatment
of COVID-19. Molnupiravir was administered at 800 mg q12h for 5 days to participants in …
of COVID-19. Molnupiravir was administered at 800 mg q12h for 5 days to participants in …